According to filings with the U.S. Securities and Exchange Commission, Vuja De Sciences is raising up to $1,000,000.00 in new funding. Sources indicate that as part of senior management Chairman, David Warshawsky played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vuja De Sciences
Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our strategy is to develop products first for osteosarcoma, a rare bone cancer that largely effects adolescents, and then extend to other cancers. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de-risk and inform product development and maximize likelihood for successful human oncology clinical trials. We are testing repurposed drugs that have previously been in human clinical trials, as well as novel preclinical drugs. In Comparative Oncology, canine patients with naturally occurring cancer are included in clinical trials for benefit of humans and humans best friend. Dog osteosarcoma is highly relevant to human osteosarcoma; drugs effective in the dog are highly relevant to the human. A further advantage of dogs that is crucial in cancer recurrence trials is the that fact that in dogs the cancer process is sped up, so that what happens over a time frame of a few years in humans is compressed into months in dogs.

To learn more about Vuja De Sciences, visit http://vujade-life.com/

Contact:
David Warshawsky, Chairman
857-204-3628
https://www.linkedin.com/in/davidwarshawasky/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.